Clinical trials: Controlled Hypertension
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Healthy Adult Participants
Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.
- Trial name
- NCT06429930
- Testing
- L608 Liposomal inhalation suspension
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Hypertension
Comparison of Two Treatment Strategies in Hypertensive Patients
The purpose of the study is to determine whether a specific training of General Practitioners (Family Physicians) regarding the new official guidelines for the treatment of hypertension results in a higher control of high Blood…
- Trial name
- NCT00171444
- Testing
- Medical education
- Volunteers
- 4,445 people
- Sponsor
- Novartis
Healthy, Diabetes
Safety for 24 Weeks Intake of Korean Red Ginseng in Adults
Korean Red Ginseng appears to adverse events in adults taking 24 weeks Placebo and comparative assessment. And exploratory as Korean Red Ginseng blood sugar control, reduce body fat, URTI prevention, cardiovascular risk, renal…
- Conditions
- Healthy, Diabetes, Hypertension, Hyperlipidemia
- Trial name
- NCT02428998
- Testing
- Korean Red Ginseng
- Where
- South Korea
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Korea Ginseng Corporation
Primary Hypertension
Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension
The purpose of Iberis-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with primary hypertension by using Iberis multielectrode renal denervation system
- Trial name
- Iberis-HTN (NCT02901704)
- Testing
- Renal Denervation System (AngioCare)
- Volunteers
- 216 people
- Sponsor
- Shanghai AngioCare Medical
Pulmonary Arterial Hypertension
Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension
This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60…
- Trial name
- NCT04483115
- Testing
- TPN171H, Tadalafil
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Vigonvita Life Sciences
Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum…
- Trial name
- ZENITH (NCT04896008)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension
Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT)
The HYIMPACT study (IMPACT of Nebilet® in Blood Pressure Control in Patients with Hypertension) is a multinational, multicenter, observational, prospective, longitudinal real-world evidence study designed to assess the…
- Trial name
- HYIMPACT (NCT06938516)
- Where
- 49 sites in Indonesia, Malaysia and 5 more
- Volunteers
- 4,537 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
Essential Hypertension
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of…
- Trial name
- NCT00415038
- Testing
- Rostafuroxin
- Where
- Belgium
- Volunteers
- 438 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Adults With Uncontrolled Hypertension
Single-arm Study of Symplicity™ Renal Denervation System in Patients With Uncontrolled HyperTensioN in India
This study is to evaluate efficacy and safety of renal denervation in the treatment of uncontrolled hypertension. This study will enroll a minimum of 40 and a maximum of 45 subjects.
- Trial name
- HTN-India (NCT01632943)
- Testing
- Symplicity renal denervation system
- Where
- India
- Volunteers
- 14 people
- Sponsor
- Medtronic Vascular
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Portal Hypertension
A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension
The purpose of this trial is to investigate safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) after intravenous (IV) administration of FE 204205 in patients with cirrhotic portal hypertension.
- Trial name
- NCT02929407
- Testing
- FE 204205
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Ferring Pharmaceuticals
Raised Intraocular Pressure
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).
- Trial name
- NCT01173471
- Testing
- AZD4017
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Hypertension, Primary Hypercholesterolaemia
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary…
- Trial name
- HODO-2224 (NCT06646354)
- Testing
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Hyundai Pharm
Hypertension
Irbesartan and Amlodipine Combination in Controlling Blood Pressure
The primary objective is to compare the extent of reduction of mean Seated Diastolic Blood Pressure (SeDBP) at the end of 8 weeks between each Fixed Dose Combination (FDC), its individual constituents administered as monotherapy…
- Trial name
- I-COMBO (NCT00950066)
- Testing
- IRBESARTAN (SR47436), Amlodipine, Irbesartan / Amlodipine
- Where
- 4 sites in India, Philippines and 2 more
- Volunteers
- 270 people
- Sponsor
- Sanofi
Liver Cirrhosis
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.
- Trial name
- NCT00592475
- Testing
- conivaptan
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cumberland Pharmaceuticals
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Postmenopause, Hypertension
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.
- Conditions
- Postmenopause, Hypertension, Pre-Hypertension
- Trial name
- NCT00420342
- Testing
- Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
- Where
- 9 sites in United States
- Volunteers
- 92 people
- Sponsor
- Bayer
Cataract, Glaucoma
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension…
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Trial name
- NCT07218796
- Testing
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- SpyGlass Pharma, Inc.